Arcutis Biotherapeutics, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved ZORYVE® (roflumilast) Cream 0.15% for the treatment of mild-to-moderate atopic dermatitis (AD) in adult and
The American Academy of Dermatology’s 2016 guidelines for the management of acne vulgaris were updated with a systematic review in 2024. This review put forward strong recommendations for topical treatments
Dermatology Times recently published an article about Olympic athlete Suni Lee’s journey with atopic dermatitis (AD). This insightful piece featured comments from Alexandra K. Golant, MD, a board-certified dermatologist, medical
The U.S. Food and Drug Administration (FDA) recently approved Botanix’s Sofdra™ (sofpironium) topical gel 12.45% for the treatment of primarily axillary hyperhidrosis in adults and children ages 9 and above.
LEO Pharma recently announced that the U.S. Food and Drug Administration (FDA) has approved its new Adbry® (tralokinumab-ldrm) 300 mg single-dose autoinjector for adult patients. Adbry, which is a high-affinity fully
The Global Hidradenitis Suppurativa Atlas (GHiSA), an international non-profit organization, has produced its first report on Hidradenitis Suppurativa (HS). This comprehensive overview of HS was produced with the International League
As health care providers, staying informed and having access to the latest information on Hidradenitis Suppurativa (HS) is crucial to ensuring you provide optimal care to your patients with this
As we close out the month of May and Asian American and Pacific Islander Heritage Month, it seems an opportune time to reflect on providing culturally competent and equitable dermatological
A review recently published in JAMA Dermatology analyzed the current state of artificial intelligence (AI) dermatology mobile applications (apps), looking specifically at their purpose, supporting evidence, regulatory status, clinician input,
Rosacea, a common facial skin disease, is estimated to affect over 16 million Americans. According to the National Rosacea Society, “Rosacea may develop in many ways and at any age,
A recent study reviewed the use of cosmetic injectables in individuals with skin of color (S0C) with the aim of assessing their uses, effectiveness, and safety. SoC populations are increasingly
Andrew F. Alexis, MD, MPH, was recently honored at the second annual Fleur De Cure event in New York City. This special gathering, organized by the National Psoriasis Foundation and
The U.S. Food and Drug Administration (FDA) has issued a warning to all health care professionals and consumers revealing that counterfeit versions of Botox (botulinum toxin) have been uncovered in
Global biopharmaceutical company, UCB, recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for BIMZELX® (bimekizumab-bkzx) for the treatment
The U.S. Food and Drug Administration (FDA) has issued a warning to consumers to not use certain over-the-counter (OTC) pain relief products due to the potential for dangerous health effects.
Johnson & Johnson recently announced the first data from their FRONTIER 2 clinical trial which evaluated JNJ-2113. This is the first and only investigational targeted oral peptide designed to block
A recent study revealed that multispectral imaging could provide promising accuracy when predicting the progression of pediatric morphea. Morphea, also known as localized scleroderma, is described as “an inflammatory, fibrosing
Recent revelations about the presence of benzene in benzoyl peroxide (BPO)-containing acne products have put dermatologists in a challenging position. Patients are understandably concerned about the safety of their acne
In recent breaking news, concerns surrounding benzene contamination have resurfaced, sparking renewed health worries and heightened regulatory scrutiny. Valisure LLC, an independent laboratory facility, has revealed the results of its
JNJ-77242113 has been evaluated for its efficacy in the treatment of moderate-to-severe plaque psoriasis. An IL-23-receptor antagonist peptide, it selectively blocks interleukin-23 signaling and downstream cytokine production and can be
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
